AstraZeneca shares fall despite Imfinzi survival-test win
AstraZeneca’s U.S. shares (AZN) fell about 0.7% to $161.51 even after Imfinzi, with Amgen’s Imdelltra, significantly extended survival among patients in a late-stage lung-cancer study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.